10,000 heart patients enrolled in quest to predict sudden death
NCT ID NCT07336290
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will enroll 10,000 adults with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens. Researchers will combine genetic tests, advanced heart imaging, and blood markers to create better tools for early diagnosis and to predict risks like sudden cardiac death or heart failure. Participants will be followed every six months for up to three years. No drugs or devices are being tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to diagnose HCM and predict who is at risk of sudden cardiac death or heart failure.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly change patient care, and results may take years to apply in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart scan AI could predict sudden cardiac death risk in common heart condition
- Experimental pill aims to ease thick heart muscle symptoms
- Massive HCM database aims to unlock better heart care
- Heart drug swap tested for safer symptom control
- Real-World HCM drug use under the microscope
- Heart drug mavacamten shows promise in Real-World study